Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro.
The replication of herpes simplex virus (HSV) type 1 and 2 in Vero cells is inhibited in the presence of enterocin CRL35 (ECRL), a bacteriocin produced by Enterococcus faecium CRL35. Attempts to resolve the mode of action of ECRL indicate that virus adsorption and penetration are not affected. Instead, a late step of virus multiplication is hindered since the addition of 100 microg/ml of ECRL at 8h post infection still causes a 90% inhibition of virus release. The effect of ECRL on HSV antigen expression was studied by immunofluorescence using a polyclonal serum and a monoclonal antibody against glycoprotein D (gamma protein). These studies indicated that ECRL impeded the second round of infection, apparently as a consequence of the inhibition of glycoprotein D expression. The replication of syncytial mutants of HSV-1 was significantly inhibited at a ECRL concentration of 25 microg/ml. Both the percentage of fused cells and the polykaryocyte size were affected. Studies on the effect of ECRL on viral protein synthesis showed that in the presence of ECRL, HSV late gamma proteins were not synthesized. From these findings, it is concluded that inhibition of HSV spreading by ECRL is due to the prevention of mainly late glycoprotein synthesis.
Wachsman
Mónica B
MB
Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, Piso 4, 1428 Buenos Aires, Argentina. wachsman@qb.fcen.uba.ar
Castilla
Viviana
V
de Ruiz Holgado
Aida P
AP
de Torres
Ramón A
RA
Sesma
Fernando
F
Coto
Celia E
CE
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001430:Bacteriocins / Q000494:pharmacology*; D002522:Chlorocebus aethiops; D003601:Cytotoxicity Tests, Immunologic; D019084:Fluorescent Antibody Technique, Indirect; D015726:Giant Cells / Q000378:metabolism; D006023:Glycoproteins / Q000378:metabolism; D018259:Herpesvirus 1, Human / Q000187:drug effects* / Q000502:physiology; D018258:Herpesvirus 2, Human / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D014709:Vero Cells; D014764:Viral Proteins / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D001430:Bacteriocins; D006023:Glycoproteins; D014764:Viral Proteins; C121783:enterocin CRL35